Macitentan

Macitentan
Clinical data
Trade names Opsumit
Synonyms ACT-064992
License data
Pregnancy
category
  • US: X (Contraindicated)
    Routes of
    administration    		 Oral
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Metabolism Hydrolysis, oxidation (CYP3A4)
    Excretion 2/3 urine, 1/3 faeces
    Identifiers
    CAS Number
    PubChem CID
    ChemSpider
    KEGG
    ChEBI
    Chemical and physical data
    Formula C19H20Br2N6O4S
    Molar mass 588.28 g·mol−1
    3D model (JSmol)

    Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH).[1] The other two ERAs marketed as of 2014 are bosentan and ambrisentan.[1] Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB.[1] However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.[2] The drug received approval from the U.S. Food and Drug Administration (FDA) on October 13, 2013.[3]

    Mechanism of action

    Endothelin and endothelin receptors

    Endothelin (ET) is an extremely potent blood vessel constricting substance that is secreted by endothelial cells.[4] In the lungs, the most common ET form released is ET-1.[4] ET-1 release can occur through both constitutive and non-constitutive pathways.[4] Upon release, ET-1 can bind to the ET receptors that are expressed on arterial smooth muscle cells and fibroblasts in the lungs.[4] ET receptors are G protein coupled receptors and, when activated, lead to an increase in intracellular calcium levels via the Gαq signaling pathway.[4] The rise in intracellular calcium leads to contraction of the arterial smooth muscle, as well as vascular remodelling due to cell proliferation.[4] Prolonged constriction and fibrosis are factors in the pathogenesis of PAH.[1]

    Role of macitentan

    Macitentan blocks the ET1-dependent rise in intracellular calcium by inhibiting the binding of ET-1 to ET receptors. Blocking of the ETA receptor subtype seems to be of more importance in the treatment of PAH than blocking of ETB, likely because there are higher numbers of ETA receptors than ETB receptors in pulmonary arterial smooth muscle cells.[4]

    Experimental pharmacokinetics

    Macitentan has slow association kinetics.[4] Its potency increases 6.3-fold when it is pre-incubated with pulmonary arterial smooth muscle cells for 120 minutes compared to 10 minutes with pulmonary arterial smooth muscle cells.[4] Macitentan also has a high receptor occupancy half-life (approximately 17 minutes) compared to bosentan (approximately 70 seconds) and ambrisentan (approximately 40 seconds).[4] This increased receptor occupancy half-life allows macitentan to act as a non-competitive antagonist of ET receptors.[4] Bosentan and ambrisentan are both competitive antagonists.[4]

    Pharmacokinetics

    Macitentan is taken as a 10 mg oral dose once a day.[1] Its half-life in humans is about 16 hours and steady state is reached by the third day of administration.[5] It is absorbed slowly into the plasma.[6] Macitentan dealkylates into the active metabolite ACT-132577, which reaches its peak plasma concentration about 30 hours after the first dose is administered, and has a half-life of approximately 48 hours.[6] Although ACT-132577 has a lower affinity for the ET receptors than its parent compound,[2] It maintains higher plasma concentrations than macitentan.[6] Both compounds can be excreted from the body through the urine or feces.[5]

    Co-administration of ciclosporin has only a slight effect on the concentrations of macitentan and its active metabolite, while rifampicin decreases the area under the curve (AUC) of the drug's blood plasma concentration by 79%, and ketoconazole approximately doubles it. This corresponds to the finding that macitentan is mainly metabolised via the liver enzyme CYP3A4.[7]

    ACT-132577, the active metabolite of macitentan

    References

    1. 1 2 3 4 5 Hong, I.S., Coe, H.V., & Catanzaro, L.M. (2014). Macitentan for the treatment of pulmonary arterial hypertension. The Annals of Pharmacotherapy, 48, 1-10.
    2. 1 2 Iglarz, M., Qiu, C., Fischli, W., Morrison, K., Binkert, C., Clozel, M., Hess, P., Capeleto, B., Buchmann, S., Boss, C., Bolli, M.H., Weller, T., Treiber, A., & Gatfield, J. (2008). Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. Journal of Pharmacology and Experimental Therapeutics, 327(3), 736-745.
    3. ↑ Actelion receives us fda approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension Archived 2013-10-23 at the Wayback Machine.. Actelion. Retrieved 22 October 2013.
    4. 1 2 3 4 5 6 7 8 9 10 11 12 Gatfield, J., Grandjean, C. M., Sasse, T., Clozel, M., & Nayler, O. (2012). Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS ONE, 7(10), e47662.
    5. 1 2 Bruderer, S., Hopfgartner, G., Seiberling, M., Wank, J., Sidharta, P.N., Treiber, A., & Dingemanse, J. (2012). Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica, 42(9), 901-910.
    6. 1 2 3 Sidharta, P.N., van Giersbergen, P.L., Halabi, A., & Dingemanse, J. (2011). Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol, 67, 977–984.
    7. ↑ Bruderer, S.; Äänismaa, P. I.; Homery, M. C.; Häusler, S.; Landskroner, K.; Sidharta, P. N.; Treiber, A.; Dingemanse, J. (2011). "Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist". The AAPS Journal. 14 (1): 68–78. doi:10.1208/s12248-011-9316-3. PMC 3282010. PMID 22189899.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.